{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:34:19Z","timestamp":1787909659878,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIAID\/NIH, Department of HHS, under Vaccine Training Evaluation Unit"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.vaccine.2015.10.072","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T09:04:34Z","timestamp":1445936674000},"page":"6719-6726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phase 1 testing of detoxified LPS\/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis"],"prefix":"10.1016","volume":"33","author":[{"given":"Alan S.","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Billington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"DeFilippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwaldeep K.","family":"Bajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Jun (26)","key":"10.1016\/j.vaccine.2015.10.072_bib0255","first-page":"2542","article-title":"Emerging Infections program healthcare-associated infections and antimicrobial use prevalence survey team survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0260","series-title":"National hospital discharge survey data brief, No. 6","first-page":"1","article-title":"Inpatient care for septicemia or sepsis: a challenge for patients and hospitals","author":"Hall","year":"2011"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0265","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1215093","article-title":"The future of antibiotics and resistance","volume":"368","author":"Spellberg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0270","doi-asserted-by":"crossref","first-page":"e34953","DOI":"10.1371\/journal.pone.0034953","article-title":"Antibiotic resistance is prevalent in an isolated cave microbiome","volume":"7","author":"Bhullar","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0275","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10388","article-title":"Antibiotic resistance is ancient","volume":"477","author":"D\u2019Costa","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0280","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0285","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/jama.276.14.1181","article-title":"Prevention of systemic infections, especially meningitis, caused by Haemophilus influenza type b. Impact on public health and implications for other polysaccharide-based vaccines","volume":"276","author":"Robbins","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0290","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1128\/IAI.05484-11","article-title":"Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis","volume":"79","author":"Simon","year":"2011","journal-title":"Infect Immun"},{"issue":"May (19)","key":"10.1016\/j.vaccine.2015.10.072_bib0295","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1073\/pnas.0900891106","article-title":"Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates","volume":"106","author":"Robbins","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Jul (1)","key":"10.1016\/j.vaccine.2015.10.072_bib0300","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1172\/JCI113062","article-title":"Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans","volume":"80","author":"Cryz","year":"1987","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.072_bib0305","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1128\/IAI.58.2.373-377.1990","article-title":"Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines","volume":"58","author":"Cryz","year":"1990","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0310","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0264-410X(86)90092-7","article-title":"Safety and immunogenicity of polyvalent Klebsiella capsular polysaccharide vaccine in humans","volume":"4","author":"Cryz","year":"1986","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0315","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0264-410X(94)80054-4","article-title":"Phase I trial of a 23-valent Klebsiella capsular polysaccharide vaccine and an eight valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously","volume":"12","author":"Edelman","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0320","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJM198211113072001","article-title":"Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli","volume":"307","author":"Ziegler","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0325","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/infdis\/173.5.1157","article-title":"A non-covalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against Gram-negative bacteremia","volume":"173","author":"Bhattacharjee","year":"1996","journal-title":"J. Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0330","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/infdis\/170.3.622","article-title":"Affinity-purified Escherichia coli J5 lipopolysaccharide specific IgG protects neutropenic rats against Gram-negative bacterial sepsis","volume":"170","author":"Bhattacharjee","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0335","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1086\/498167","article-title":"Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms","volume":"192","author":"Opal","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0340","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1753425908095959","article-title":"Intranasal administration of a detoxified endotoxin vaccine protects against heterologous Gram-negative bacillary pneumonia","volume":"14","author":"Chen","year":"2008","journal-title":"Innate Immunity"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0345","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00004630-200209000-00006","article-title":"Differential effects of two different routes of immunization on protection against Gram-negative sepsis by a detoxified E. coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine in a burned mouse model","volume":"23","author":"Neely","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0350","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/319297","article-title":"Active immunization with a detoxified E. coli J5 lipopolysaccharide-group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis","volume":"183","author":"Cross","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0355","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1016\/S0264-410X(03)00483-3","article-title":"Phase I study of detoxified Escherichia coli J5 lipopolysaccharide\/group B meningococcal outer membrane protein complex vaccine to human subjects","volume":"21","author":"Cross","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0360","first-page":"87","article-title":"CpG ODN as a TH1 immune enhancer for prophylactic and therapeutic vaccines","volume":"vol. 6","author":"Krieg","year":"2005"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0365","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1086\/533467","article-title":"CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years","volume":"46","author":"Cooper","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0370","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0375","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/653112","article-title":"Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a TLR9 agonist-adjuvant: A randomized trial","volume":"51","author":"S\u00f8gaard","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.072_bib0380","doi-asserted-by":"crossref","first-page":"e46094","DOI":"10.1371\/journal.pone.0046094","article-title":"Phase 1 study in malaria na\u00efve adults of BSAM2\/Alhydrogel\u00ae+CPG 7909, a blood stage vaccine against P. falciparum malaria","volume":"7","author":"Ellis","year":"2012","journal-title":"PLoS ONE"},{"issue":"Jun (30)","key":"10.1016\/j.vaccine.2015.10.072_bib0385","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.vaccine.2013.04.063","article-title":"Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers","volume":"31","author":"Hopkins","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0390","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1021\/cr020373d","article-title":"Electroluminescence (ECL)","volume":"104","author":"Richter","year":"2004","journal-title":"Chem Rev"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0395","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/cir202","article-title":"Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention","volume":"53","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0400","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/cis552","article-title":"Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms","volume":"55","author":"Neidel","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.072_bib0405","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMp0804651","article-title":"Antibiotic-resistant bugs in the 21st century\u2014a clinical superchallenge","volume":"360","author":"Arias","year":"2009","journal-title":"N Engl J Med"},{"issue":"Apr","key":"10.1016\/j.vaccine.2015.10.072_bib0410","article-title":"Antibacterial drug shortages from 2001\u20132013: implications for clinical practice","author":"Quadri","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0415","unstructured":"Executive Order-National Strategy for Combating Antibiotic-Resistant Bacteria. Issued by the Office of the Press Secretary, The White House, September 18, 2014."},{"key":"10.1016\/j.vaccine.2015.10.072_bib0420","first-page":"566","article-title":"The therapeutic activity of gamma globulin; chloramphenicol combinations in mouse infections due to Salmonella pneumococci, Escherichia coli, or Pasteurella","volume":"5","author":"Manning","year":"1957","journal-title":"Antibiot Annu"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0425","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4049\/jimmunol.111.2.433","article-title":"Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-Gal epimerase-deficient mutant","volume":"111","author":"Ziegler","year":"1973","journal-title":"J Immunol"},{"issue":"Aug (2)","key":"10.1016\/j.vaccine.2015.10.072_bib0430","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/infdis\/158.2.301","article-title":"McCabe WR Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects","volume":"158","author":"DeMaria","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0435","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4049\/jimmunol.100.2.292","article-title":"A proposed mechanism for natural immunity to enterobacterial pathogens","volume":"100","author":"Chedid","year":"1968","journal-title":"J Immunol"},{"issue":"8446","key":"10.1016\/j.vaccine.2015.10.072_bib0440","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(85)90176-X","article-title":"Prevention of Gram negative shock and death in surgical patients by antibody to endotoxin core glycolipid","volume":"2","author":"Baumgartner","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0445","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0264-410X(99)00230-3","article-title":"Immunotherapy of sepsis: flawed concept or faulty implementation?","volume":"17","author":"Cross","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0450","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1172\/JCI111150","article-title":"Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core","volume":"72","author":"Pollack","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0455","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00000658-199303000-00013","article-title":"Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome","volume":"217","author":"Nys","year":"1993","journal-title":"Ann Surg"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0460","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/00003246-199109000-00003","article-title":"Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial","volume":"9","author":"Schedel","year":"1991","journal-title":"Crit Care Med"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0465","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3109\/00365548909021700","article-title":"Preliminary study on treatment of septic shock patients with antilipopolysaccharide IgG from blood donors","volume":"21","author":"Fomsgaard","year":"1989","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0470","first-page":"1","article-title":"Intestinal dysbiosis following cholestasis is reduced by active immunization with a detoxified endotoxin vaccine","volume":"2","author":"Alaish","year":"2015","journal-title":"J Bacter Mycol"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0475","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1001\/jama.2010.1553","article-title":"Long-term cognitive impairment and functional disability among survivors of severe sepsis","volume":"304","author":"Iwashyna","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0480","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/jama.2010.1546","article-title":"The lingering consequences of sepsis: a hidden public health disaster?","volume":"304","author":"Angus","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0485","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2010.761","article-title":"Long-term acute care hospitalization after critical illness","volume":"303","author":"Kahn","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0490","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/jama.1997.03540370048035","article-title":"Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group","volume":"277","author":"Quartin","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.10.072_bib0495","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/clinids\/23.1.179","article-title":"Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an 8-valent Pseudomonas O-polysaccharide conjugate vaccine administered to acute trauma victims","volume":"23","author":"Campbell","year":"1931","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2015.10.072_bib0500","unstructured":"Intercell News release, November 9, 2010."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15015017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15015017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T16:52:11Z","timestamp":1692118331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15015017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":50,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0264410X15015017"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 testing of detoxified LPS\/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}